Tofacitinib in the treatment of ulcerative colitis: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH)

Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease (IBD). Despite the widening range of drug treatment options, primary nonresponse, secondary loss of response as well as adverse events call for additional treatment alternatives. Tofacitinib is an oral small-molecule drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Kutschera, Maximilian, Novacek, Gottfried, Reinisch, Walter, Högenauer, Christoph, Petritsch, Wolfgang, Haas, Thomas, Moschen, Alexander, Dejaco, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Consensus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713195/
https://www.ncbi.nlm.nih.gov/pubmed/36454302
http://dx.doi.org/10.1007/s00508-022-02110-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713195/
https://www.ncbi.nlm.nih.gov/pubmed/36454302
http://dx.doi.org/10.1007/s00508-022-02110-2

Ejemplares similares